Austria · Delayed Price · Currency is EUR Pentixapharm Holding AG Company Description
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals.
The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study.
It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company’s PentixaFor is being developed as a diagnostic tool for primary aldosteronism, a cause of hypertension, which is in Phase III trial.
Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008.
Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
| Country | Germany |
| Founded | 2019 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 75 |
| CEO | Dirk Pleimes |
Contact Details
Address: Robert-Rössle-Straße 10 Berlin, 13125 Germany | |
| Phone | 49 30 9489 2600 |
| Website | pentixapharm.com |
Stock Details
| Ticker Symbol | PTPN |
| Exchange | Vienna Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dirk Pleimes | Chief Executive Officer |
| Jenny Schewe | Chief Financial Officer |